PHR (NYSE: PHR) insider files Form 144 for 975-share planned sale
Rhea-AI Filing Summary
A Form 144 notice indicates that an insider associated with PHR plans to sell up to 975 shares of common stock through Fidelity Brokerage Services LLC on or about 01/15/2026 on the NYSE. The shares to be sold have an indicated aggregate market value of $15,970.01, and there were 60,287,003 shares of this class outstanding at the time referenced.
The 975 shares were acquired on 01/14/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Balaji Gandhi sold additional common shares in two transactions: 885 shares on 10/17/2025 for $19,789.66 and 8,009 shares on 01/08/2026 for $136,209.87. The signer represents that they are not aware of undisclosed material adverse information about the issuer’s operations.
Positive
- None.
Negative
- None.
FAQ
How many PHR shares are planned for sale under this Form 144?
The notice covers an intended sale of 975 shares of PHR common stock, with an indicated aggregate market value of $15,970.01.
How and when were the 975 PHR shares acquired?
The 975 shares were acquired on 01/14/2026 through restricted stock vesting from the issuer as compensation.
What is the approximate sale date and trading venue for these PHR shares?
The approximate sale date listed is 01/15/2026, with the shares to be sold on the NYSE through Fidelity Brokerage Services LLC.
How many PHR shares are outstanding according to this notice?
The filing states that there are 60,287,003 shares of the relevant class of PHR common stock outstanding.
What PHR share sales has Balaji Gandhi made in the past three months?
Over the past three months, Balaji Gandhi sold PHR common shares in two transactions: 885 shares on 10/17/2025 for $19,789.66 and 8,009 shares on 01/08/2026 for $136,209.87.
Does the insider make any representation about undisclosed adverse information on PHR?
Yes. By signing the notice, the person for whose account the securities are to be sold represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.